Since phase 3 trials for diabetic retinopathy show ruboxistaurin is a well-tolerated inhibitor of PKC, we believe it could be relatively quick to translate to the clinic, providing a novel therapeutic pathway to treat neutrophil-mediated immunopathology in COVID-19 [23]. This evidence concerns the gene PRRT2 and COVID-19.